Overall Status

Recruiting (3)

Active, not recruiting (1)

Completed (1)

Phase

early phase 1 (1)

phase 2 (1)

phase 3 (1)

Sponsor

Menzies School of Health Research (1)

Oregon Health and Science University (1)

SWISS BIOPHARMA MED GmbH (1)

U.S. Wound Registry (1)

Valenta Pharm JSC (1)

Collaborator

Cooperative Research Centre for Aboriginal Health (1)

Murdoch Childrens Research Institute (1)

University of Melbourne (1)

Intervention

baricitinib (1)

benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium (1)

hydroxymethylquinoxalindioxyde (1)

monoclonal antibody (mab) sb24m (1)

usual care (1)

Study Documents

Intervention Type

drug (2)

biological (1)

other (1)

Funder Type

Other (4)

Industry (1)

Study Type

Interventional (3)

Observational (1)

Observational [Patient Registry] (1)

pyoderma

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Pyoderma Trial in Russian Federation (Hydroxymethylquinoxalindioxyde, Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium)

Recruiting

Pyoderma

Chelyabinsk, Russian Federation
+9 more

Sep 27, 2022

Pyoderma, Pyoderma Gangrenosum, Pyoderma Vegetans Trial in Minsk, Riga (Monoclonal antibody (Mab) sB24M)

Active, not recruiting

Pyoderma
+3 more

Monoclonal antibody (Mab) sB24M

Minsk, Belarus
+1 more

Jul 8, 2022

Pyoderma Gangrenosum, Skin Diseases, Wound Heal Trial in Portland (Baricitinib)

Recruiting

Pyoderma Gangrenosum
+4 more

Baricitinib

Portland, Oregon

Oregon Health and Science University

Sep 8, 2021

Diabetic Foot, Varicose Ulcer, Pressure Ulcer Trial in The Woodlands (Usual care)

Recruiting

Diabetic Foot
+14 more

Usual care

The Woodlands, Texas

US Wound Registry

Apr 30, 2018

Regional Healthy Skin Program in Remote Aboriginal Communities

Completed

Scabies
+3 more

Casuarina, Northern Territory, Australia

Menzies School of Health Research

Apr 20, 2009